Psychiatric Annals
September 1, 2022
Mitch Earleywine, Zachary Herrmann
5 citations
Initial promise and dire need have inspired the multiple research programs of the second psychedelic renaissance. Serotonergic psychedelics (psilocybin, lysergic acid diethylamide, and ayahuasca) have decreased end-of-life anxiety in cancer patients, treatment-resistant depression, alcohol dependence, social anxiety in autistic adults, and nicotine dependence when applied with supportive...
Psychiatric Annals
September 1, 2022
Brian S. Barnett, Jeremy Weleff
6 citations
Growing evidence from observational studies and clinical trials suggests that psychedelics such as lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin may hold treatment potential for alcohol, opioid, tobacco, and other substance use disorders (SUDs). The mechanisms by which psychedelics might exert therapeutic efficacy in these conditions have not been fully...
Cureus
September 1, 2022
Joshua S Kurtz, Neal A Patel, Julian L Gendreau et al.
35 citations
Although early therapeutic research on psychedelics dates back to the 1940s, this field of investigation was met with many cultural and legal challenges in the 1970s. Over the past two decades, clinical trials using psychedelics have resumed. Therefore, the goal of this study was to (1) better characterize the recent uptrend in psychedelics in clinical trials and (2) identify areas where...
Transcultural Psychiatry
August 29, 2022
Ayse Ceren Kaypak, Amir Raz
17 citations
To date, the clinical and scientific literature has best documented the effects of classical psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), in typical quantities most often associated with macrodosing. More recently, however, microdosing with psychedelics has emerged as a social trend and nascent therapeutic intervention. This variation in...
PLoS One
August 24, 2022
Mary M. Sweeney, Sandeep M. Nayak, Ethan Hurwitz et al.
60 citations
Both psychedelic drug experiences and near-death experiences can occasion changes in perspectives on death and dying, but there have been few direct comparisons of these phenomena. This study directly compared psychedelic occasioned and non-drug experiences which altered individuals’ beliefs about death. Individuals who reported an experience that altered their beliefs about death occasioned by...
Neuropharmacology
August 22, 2022
Charles D. Nichols
31 citations
Psychedelics have seen a resurgence of interest from both the scientific and lay community in recent years. Psychedelics are known for their ability to produce profound perceptual alterations, ego dissolution, and separation from reality in humans. Virtually all research into psychedelics and their mechanism of action has focused on examining effects in the brain, and on consciousness....
Journal of Psychoactive Drugs
August 19, 2022
Marcio S. C. Longo, Bheatrix Bienemann, Marco Multedo et al.
10 citations
This study sought to investigate the effects of different substances on nature relatedness (NR) in the general population. An online cross-sectional survey done in Brazil investigated use of ayahuasca/DMT, psilocybe mushrooms, LSD, MDMA/ecstasy, cocaine, cannabis, and alcohol. NR was assessed using the short-form version of the nature related scale (NR-6). One-way analysis of variance (ANOVA)...
Addiction
August 17, 2022
Ofir Livne, Dvora Shmulewitz, Claire A Walsh et al.
90 citations
Abstract Background and Aims Hallucinogen use is potentially harmful. Information on whether such use has increased in recent decades is lacking. This study assessed overall and age‐specific time trends in the prevalence of 12‐month hallucinogen use in the US general population. Design Cross‐sectional. Setting Data from the US National Survey on Drug Use and Health, 2002–19. Participants...
Archives of Clinical Neuropsychology
August 17, 2022
Brian Peacock
3 citations
Abstract Objective: Psychedelic-assisted therapies are emerging as safe and effective treatments for some psychological conditions including depression, anxiety, posttraumatic stress disorder, and substance use disorders. As ketamine therapy is already available in general medicine and 3,4 Methylenedioxymethamphetamine (MDMA) and psilocybin are in late-stage clinical trials, neuropsychologists...
Journal of Psychopharmacology
August 16, 2022
Brian S. Barnett, Kathleen M Ziegler, Rick Doblin et al.
15 citations
BACKGROUND: In 1967, concerns about the carcinogenic potential of psychedelics arose after a study reported chromosomal damage in human leukocytes following in vitro lysergic acid (LSD) exposure. Worries were further heightened by subsequent reports of leukemia and other cancers in LSD users. Additional investigations of psychedelics' effects on chromosomes were published over the next decade,...